earnings
confidence high
sentiment positive
materiality 0.65
Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL
Marker Therapeutics, Inc.
2025-Q3 EPS reported
-$0.75
revenue$2,443,225
- Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
- Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).
- APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.
- First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.
- Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025.